A Phase I/IIA, Non-Randomized, Open Label, Single Dose, Dose-Escalation, Safety Study of BKT140, a CXCR4 Antagonist in Patients With Multiple Myeloma.
Phase of Trial: Phase I/II
Latest Information Update: 19 Apr 2016
At a glance
- Drugs BL 8040 (Primary)
- Indications Multiple myeloma; Stem cell mobilisation
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biokine Therapeutics
- 10 Jun 2017 Biomarkers information updated
- 19 Apr 2016 Results published as per BioLineRx Ltd media release.
- 03 Feb 2015 Last checked against ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History